Stacey Chang-Douglass
Clarivate
Stacey Chang-Douglass is listed at Clarivate. Stacey spoke at ISPOR Europe 2026 in November 2026 (speaker, “Beyond the Trial: Real-World Evidence and Lifecycle Evidence Generation in NICE Existing-Use HealthTech Assessments”). Speaks mainly at Government Administration events.
Compiled from published conference agendas; not yet confirmed by Stacey. Is this you? Claim this profile.
- Sector: Government Administration
About
Stacey is Head of Health Economics at Clarivate, where she oversees the delivery of economic modelling to support HTA submissions, global model development and country adaptations. With over 15 years of health economics experience spanning positions in consulting and at NICE, she provides strategic insights and technical guidance on projects across an extensive range of therapy areas. She also serves as a standing committee member at the NICE Medical Technologies Advisory Committee since 2022, a health economist member of the committee updating NICE guideline NG208, and an External Oversight Group member of the NICE Listens project on AI in health and care guidance. She holds an MSc from the London School of Economics and a PhD from the University of York.
Sessions at 1 conference
ISPOR Europe 2026 8 November 2026 – 11 November 2026
- Beyond the Trial: Real-World Evidence and Lifecycle Evidence Generation in NICE Existing-Use HealthTech Assessments Speaker · 10 November 2026
Spoke alongside
People who have shared a session with Stacey at events on B2DB.
- Anastasia Chalkidou NICE 1 shared session
- Dawn Lee University of Exeter PenTAG 1 shared session
- Michael Kolovetsios Johnson & Johnson MedTech 1 shared session